Cap-independent co-expression of dsRNA-sensing and NF-κB pathway inhibitors enables tunable self-amplifying RNA expression with reduced immunotoxicity
Tony K.Y. LimiD, Anne RitouxiD, Luke W PaineiD, Larissa FergusoniD, Tawab Abdul, Laura J Grundy, Ewan St. John SmithiD
Abstract
Self-amplifying RNA (saRNA) has the potential to provide durable, non-integrating transgene expression for transient gene therapy. However, its auto-replicative nature mimics viral infection, triggering innate immune responses that shut down cap-dependent translation, degrade cellular mRNA, induce cell death, and release cytokines. In non-immunotherapy applications, this immune activation is undesirable as it limits transgene expression, induces unintended changes in host gene expression, depletes transfected cells, and promotes inflammation--ultimately undermining therapeutic outcomes. Moreover, the use of exogenous immune suppressants to mitigate these effects often increases treatment complexity and the risk of unintended systemic side effects. To address these challenges, we developed a strategy to encode broad-spectrum innate immune suppression directly within saRNA. This approach leverages cap-independent translation to bypass saRNA-triggered translation shutdown, enabling the expression of multiple inhibitors targeting diverse double-stranded RNA-sensing and inflammatory signalling pathways. In mouse primary fibroblast-like synoviocytes--key cells in joint pathologies--this strategy eliminates the need for external immune inhibitors, reduces cytotoxicity and antiviral cytokine secretion, and enables sustained transgene expression that can be controlled with a small-molecule antiviral. Together, these findings support the development of reversible immune-evasive saRNA constructs for transient gene therapy applications that avoid persistent immune activation and eliminate the need for external immune suppressants. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=175 SRC="FIGDIR/small/614636v6_ufig1.gif" ALT="Figure 1"> View larger version (35K): org.highwire.dtl.DTLVardef@18c1f36org.highwire.dtl.DTLVardef@554f8borg.highwire.dtl.DTLVardef@d9370dorg.highwire.dtl.DTLVardef@ad5ff2_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 8
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Complete substitution with modified nucleotides suppresses the early interferon response and increases the potency of self-amplifying RNA
J. E. McGee, J. R. Kirsch, … M. W. Grinstaff·bioRxiv·Sep 15, 2023
- Engineering gene expression dynamics via self-amplifying RNA with drug-responsive non-structural proteins
Parisa Yousefpour, Justin R. Gregory, … Darrell J. Irvine·bioRxiv·Jun 8, 2025
- Controlling reactogenicity while preserving immunogenicity from a self-amplifying RNA vaccine by modulating nucleocytoplasmic transport
Jason A. Wojcechowskyj, Robyn M. Jong, … Thomas Folliard·npj VaccinesPeer-reviewed·Apr 29, 2025
- Corticosteroids and cellulose purification improve respectively the in vivo translation and vaccination efficacy of self-amplifying mRNAs
Z. Zhong, S. Mc Cafferty, … N. Sanders·bioRxiv·Aug 26, 2020
- Self-amplifying RNA-based CAR T cell therapy with enhanced duration and multi-genic logic functions
Yuyang Gu, Jaehoon Choi, … Wilson W. Wong·bioRxiv·Mar 21, 2026
- Synthesis of low immunogenicity RNA with high-temperature in vitro transcription.
Monica Z. Wu, Haruichi Asahara, … Bijoyita Roy·RNAPeer-reviewed·Jan 3, 2020